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initial surgical procedure, and an incremental cost after one year
of 43.70. QALYs were 0.7675 and 0.7591 (PPH vs. MM,
respectively). The ICER for PPH vs MM was estimated at
5188.09 per QALY. Probabilistic sensitivity analysis demon-
strated the results to be robust. CONCLUSION: PPH is a valu-
able alternative to MM in patients where surgical intervention is
indicated. Efﬁcacious without compromising QoL, whilst
decreasing length of stay and OR time, PPH can be considered a
cost-effective procedure for prolapsed internal haemorrhoids.
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OBJECTIVES: This study evaluated the cost-effectiveness of ITS
versus current POPM choices in Greece from the hospital per-
spective. METHODS: Two hundred, forty-nine surgeons and
anesthesiologists were interviewed to derive the most frequent
treatment sequences for POPM for patients experiencing moder-
ate to severe post-surgical pain. These were: a) 2 days intrave-
nously administrated (IV) opioids, 2 days IV non opioids, 1 day
oral non-opioids; b) 2 days intramuscularly administrated (IM)
opioids, 2 days IV non-opioids, 1 day oral non-opioids; c) 2 days
epidural, 3 days oral non-opioids. A decision analytic model was
developed to estimate costs and effectiveness of each these
sequential treatment arms, from surgery to discharge, compared
with 2 days of ITS followed by 3 days of oral non-opioids.
Effectiveness data were obtained from ITS trials and published
literature. The resource utilisation was deﬁned by the same phy-
sician interviews and a Delphi Panel of 40 Greek physicians.
Costs included pain medication and cost of POPM-related com-
plications not covered by or exceeding the daily reimbursed
amount to the hospital, the hotel costs and ﬁnally staff time
estimated during four European Delphi Panels. The complica-
tions’ cost was estimated by the Greek Delphi panel. Sensitivity
analyses (30%) were performed on the cost of complications
and staff time estimations. RESULTS: The probability of a suc-
cessful treatment (adequate pain control and no complications)
was 76% for ITS, 49% for the ﬁrst two treatment sequencies and
72% for the third. Total cost per patient was 677–717€ for ITS
and €717, €704, €770 for the three sequences respectively. ITS
was associated with reduced staff time and fewer complications.
The model was robust with low-moderate sensitivity (€10
change of base results). CONCLUSION: The treatment sequence
of ITS dominated the currently practiced POPM treatments in
Greece indicating that ITS cost was offset by savings resulting
from reduced staff time and fewer complications.
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OBJECTIVES: Evidence on the health care costs of laparoscopic
versus open surgery remains inconclusive. Previous work has
largely used charge data to measure cost, whereas a more rel-
evant metric would be the actual transactions amounts paid.
While studies have quantiﬁed the association between surgical
site infections (SSI) and cost, there is little evidence on the
broader measure of nosocomial infections (SSI, UTI, blood and
respiratory infections). To address these issues, this study exam-
ined the effects of laparoscopic versus open surgery and nosoco-
mial infections on direct health care costs for three common
surgical procedures: cholecystectomy, hysterectomy, and appen-
dectomy. METHODS: Hospital discharge abstract data were
obtained for 4489 subjects in 10 hospitals who were treated for
cholecystectomy, hysterectomy, or appendectomy via laparo-
scopic or open procedures. Multivariable regression analyses
were performed to estimate the relationships between laparo-
scopic surgery, nosocomial infections and health care costs for
these three procedures. The models also controlled for the fol-
lowing confounders: disease severity, age, gender, insurance
status and hospital. RESULTS: Laparoscopic surgery signiﬁ-
cantly reduces the cost of these surgical procedures. For all
patients, laparoscopic surgery reduces the health care costs of
surgery by $1796 (p < 0.01). For cholecystectomies alone, lap-
aroscopic surgery reduces these costs by even more—$2457
(p < 0.01). Laparoscopic surgery reduces costs for hysterectomy
by $1888 (p < 0.01) and appendectomy by $1019 (p < 0.05)
Nosocomial infections have a large and signiﬁcant effect on costs,
increasing overall costs by $3591 (p < 0.01). The increased costs
of nosocomial infections are greatest for cholecystectomies
($5009, p < 0.01), followed by appendectomies ($3185,
p < 0.01) and hysterectomies ($2581, p < 0.01). CONCLU-
SION: Laparoscopic surgery and nosocomial infections are
major cost drivers for each of these procedures. Laparoscopic
surgery substantially reduces the costs to payers for cholecystec-
tomies, hysterectomies, and appendectomies; whereas nosoco-
mial infections have a large positive effect on transaction costs
for all three procedures.
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OBJECTIVES: In abdominal aortic aneurysm (AAA) an endo-
vascular procedure (EVAR) was introduced challenging the gold
standard of open repair (OR). RCTs comparing them from 1999
onwards showed beneﬁt in 30-day mortality for EVAR. Due to
additional experience with EVAR; complication rates and
resource consumption may have improved. The aim of this study
is to assess the efﬁcacy, safety and resource use in the ﬁrst year
post EVAR in a current population compared to the EVAR
populations included in RCTs. METHODS: Efﬁcacy, safety and
resource use data were collected retrospectively for patients
undergoing EVAR from 2004, with at least one year follow-up.
Patient population was designed to match the published trials in
terms of age, AAA size, and suitability for surgery. Descriptive
statistics were used with normative data, mean, minimum and
maximum value, number of patients with valid data and 95%
conﬁdence intervals calculated for continuous and frequencies
for discrete data. RESULTS: A total of 149 patients’ records from
UK and Dutch hospitals were analyzed. Patients in the study
were similar in terms of age and gender to the published trials,
but higher proportion had additional risk factors (diabetes,
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cardiac, renal and pulmonary disease). Inpatient and long-term
results suggest lower all cause mortality in the current population
compared to published trials. Preoperative staywas longer (2.8 vs.
1.9 days) in the retrospective data, while post-operative hospital
stay was shorter (6.4 vs. 6–8.4 days). Time spent in the operating
theater was 14–36% lower. Despite similar general (systemic) and
EVAR related complication rates, fewer patients required conver-
sion OR (0% vs. 1.5%) or re-interventions (10.1% vs. 15%).
CONCLUSION: Although this study was not comparative and
prospective, results indicate that, due to additional experience,
current EVAR procedures may have improved efﬁcacy, decreased
resource use and increased cost-effectiveness, compared with pub-
lished trials undertaken earlier in the uptake of EVAR.
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OBJECTIVES: Almost every individual will suffer an episode of
low back pain (LBP) that disrupts normal activities; however, 5%
of patients will experience severe pain and functional impairment
chronically. This group consumes approximately 90% of health
care costs for LBP, and the prognosis for recovery with non-
surgical management alone is poor. Current surgical preference is
spinal fusion (SF), which is being utilized with escalating fre-
quency. Intradiscal electrothermal therapy (IDET) is a minimally
invasive, less costly alternative to SF. This systematic review
compared clinical outcomes in patients undergoing IDET or SF
for discogenic LBP. METHODS: English-language articles pub-
lished from January 1995 through December 2006 were identi-
ﬁed through searching the PubMed database and bibliographies.
Articles were selected if disc degeneration or disruption was the
primary indication, and if follow-up outcome data included
evaluations of back pain severity, functional impairment and/or
quality of life. Data were extracted and summarized on patient
characteristics, surgical methods and clinical outcomes.
RESULTS: The search yielded 231 articles; 53 met stated criteria
(20 IDET, 33 SF). Overall, there were similar median percentage
improvements realized after IDET or SF, respectively, for 2 of the
3 outcomes evaluated: pain severity (52%, 50%), back function
(14%, 42%) and quality of life (43%, 46%). Perioperative com-
plications were common with SF (median: 14%) whereas adverse
events were rare with IDET (median: 0%). The median percent-
age of IDET patients experiencing a minimal clinically important
improvement in pain severity was 61%. CONCLUSION:
Patients with intractable discogenic LBP have a poor prognosis
for recovery with few treatment options. IDET offers a
minimally-invasive intermediate step in their continuum of care,
with symptom amelioration comparable to SF without the sur-
gical invasiveness, attendant complications and high costs. It may
be prudent to offer IDET prior to SF in carefully-selected patients
with deﬁnitive evidence of internal disc disruption.
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OBJECTIVES: Following the September 2006 agreement
between the Irish Pharmaceutical Healthcare Association (IPHA)
and Health Service Executive (HSE) pharmacoeconomic assess-
ment of technologies that may be of high cost or signiﬁcant
budget impact, may now be requested prior to reimbursement.
The aim of this paper is to describe the pharmacoeconomic
process in Ireland, currently conducted by the National Centre
for Pharmacoeconomics (NCPE). METHODS: The Department
of Health & Children (DoHC) determines which technologies
will be subject to pharmacoeconomic assessment. Following
notiﬁcation from the DoHC, a preliminary meeting between the
NCPE and the relevant pharmaceutical company is arranged, to
determine information requirements. Further meetings preceed
the submission of a formal cost-effectiveness evaluation. The
NCPE then prepares a report based on the company submission.
Finally, the company has an opportunity to review the NCPE
report, and if necessary, to appeal it. The report is then submitted
to the DoHC, where it can be used as an aid to the pricing and
reimbursement decision making process. The whole process must
take place within a 90 day period. RESULTS: Since the 2006
agreement, approximately 14 evaluations have been carried out
by the NCPE, four of which were full economic evaluations of
new drugs prior to reimbursement. The time from submission of
the NCPE report to reimbursement ranged from 1 to 2 months.
Two evaluations to inform public health policy were also con-
ducted (hepatitis B and pneumococcal conjugate vaccines).
CONCLUSION: Following recent developments, the demand
for pharmacoeconomic evaluation is set to increase. A major
strength of this process is the timeliness to the reimbursement
decision. The inﬂuence on public health interventions is already
evident, where both vaccination strategies have been adopted
into the routine infant immunisation programme. Evidence also
suggests that the evaluation process is having a positive impact
on prescribing in primary care.
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